InflaRx (NASDAQ:IFRX) Coverage Initiated at Oppenheimer

Key Points

• Oppenheimer initiated coverage with an "outperform" rating and a $5.00 price target, implying roughly a 228.95% upside from the stock's previous close.
• The stock has a consensus "Moderate Buy" from analysts (five Buys, one Hold, one Sell) and a consensus target price of $6.50, with individual targets ranging up to $14.00.
• InflaRx shares traded at $1.52 (down 2.6%), with a market cap of about $109.9M, a 52‑week range of $0.71–$1.94, recent EPS of −$0.17, and roughly 42.4% institutional ownership.

Oppenheimer assumed coverage on shares of InflaRx (NASDAQ:IFRX - Get Free Report) in a research note issued on Friday. The brokerage set an "outperform" rating and a $5.00 price target on the stock. Oppenheimer's price objective suggests a potential upside of 228.95% from the company's previous close.

A number of other analysts have also weighed in on IFRX. Raymond James Financial reaffirmed an "outperform" rating on shares of InflaRx in a research note on Wednesday, December 31st. HC Wainwright restated a "buy" rating and issued a $6.00 price target on shares of InflaRx in a report on Tuesday, December 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of InflaRx in a research report on Friday, March 27th. Finally, Guggenheim reiterated a "buy" rating and set a $14.00 price objective on shares of InflaRx in a research note on Tuesday. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.50.

InflaRx Stock Down 2.6%

IFRX stock traded down $0.04 during trading on Friday, hitting $1.52. The company had a trading volume of 81,980 shares, compared to its average volume of 590,079. InflaRx has a 52-week low of $0.71 and a 52-week high of $1.94. The company has a 50 day simple moving average of $1.01 and a 200-day simple moving average of $1.10. The firm has a market capitalization of $109.88 million, a P/E ratio of -2.03 and a beta of 1.49.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Friday, March 20th. The company reported ($0.17) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.17). The firm had revenue of ($0.04) million for the quarter, compared to the consensus estimate of $0.03 million. Sell-side analysts forecast that InflaRx will post -0.6 earnings per share for the current year.

Institutional Trading of InflaRx

A number of institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC boosted its position in shares of InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company's stock worth $8,013,000 after purchasing an additional 1,450,000 shares in the last quarter. 683 Capital Management LLC raised its stake in InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company's stock valued at $3,348,000 after buying an additional 1,065,000 shares during the last quarter. Bank of America Corp DE purchased a new stake in InflaRx in the third quarter valued at about $3,316,000. Eversept Partners LP boosted its holdings in InflaRx by 1.5% in the fourth quarter. Eversept Partners LP now owns 1,757,312 shares of the company's stock worth $1,775,000 after acquiring an additional 26,677 shares in the last quarter. Finally, Woodline Partners LP acquired a new stake in InflaRx in the first quarter worth about $766,000. 42.39% of the stock is currently owned by institutional investors.

About InflaRx

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.